Importance Aspirin use reduces the risk of colorectal carcinoma. Experimental evidence
implicates a role of RAF kinases in up-regulation of prostaglandin-endoperoxide synthase 2 …

Abstract Approximately 5% to 15% of all colorectal cancers (CRC) have an activating BRAF
somatic mutation, which may be associated with a distinct risk profile compared with tumors …

Background: BRAF mutations in colorectal cancer (CRC) are disproportionately observed in
tumors exhibiting microsatellite instability (MSI) and are associated with other prognostic …

Background Regular use of aspirin and nonsteroidal anti-inflammatory drugs (NSAIDs) for a
longer period has been inversely associated with colorectal cancer (CRC) risk. However …

Aim Colorectal cancer is a heterogeneous disease with multiple underlying genetic
mutations resulting in different phenotypes. Mutation in the v‐R af murine sarcoma viral …

Background & Aims Colorectal tumors with mutations in BRAF and microsatellite stability
(MSS) have been associated with adverse outcomes of patients. Combined tests for …

BACKGROUND: Colorectal cancer is a heterogeneous disease with multiple underlying
genetic mutations causing different clinical phenotypes. Mutation in the BRAF oncogene is a …

Background Mutation of BRAF is a predominant event in cancers with poor prognosis such
as melanoma and colorectal cancer. BRAF mutation leads to a constitutive activation of …

Background Investigations of the associations with colorectal cancer have yielded conflicting
results. The aim of our study was to synthesize the research on colorectal cancer risks in …

Background BRAF mutations occur in 5% to 10% of metastatic colorectal cancers and are
biomarkers associated with a poor prognosis. However, the outcomes with standard …